@article{ref1,
title="Spotlight on brodalumab in the treatment of plaque psoriasis: The evidence to date",
journal="Clinical, cosmetic and investigational dermatology",
year="2019",
author="Galluzzo, M. and D'Adamio, S. and Massaro, A. and Piccolo, A. and Bianchi, L. and Talamonti, M.",
volume="12",
number="",
pages="311-321",
abstract="The IL-17/IL-23 axis is now understood to influence psoriasis, and the development of novel IL-17 inhibitor medications marks a sea change in the treatment of psoriasis. Brodalumab is a recombinant, fully human immunoglobulin IgG2 monoclonal antibody specifically targeted against IL-17RA. This article discusses the mechanism of action and the efficacy and safety profile of brodalumab presented in the literature. Brodalumab, the latest approved anti-IL-17-class medication, is the only one that exerts its effects on IL-17C as well as on IL-17A and IL-17F, blocking the shared IL-17 receptor A. In this sense, considering the recent evidence, brodalumab could have beneficial effects not only on psoriasis, but also on atopic dermatitis. It could also serve as a therapeutic alternative in patients who develop paradoxical eczematous reactions or atopic-like dermatitis during treatment with other anti-IL-17A (secukinumab, ixekizumab). © 2019 Galluzzo et al.<p /><p>Language: en</p>",
language="en",
issn="1178-7015",
doi="10.2147/CCID.S165605",
url="http://dx.doi.org/10.2147/CCID.S165605"
}